Paasa Logo
Regeneron Pharmaceuticals, Inc. logo
REGNNASDAQMarket closedOpens 9:30am ET

Regeneron Pharmaceuticals, Inc.

$788.04Last updated
-$7.98 (1.00%)Past day
Timezone

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is trading at $788.04, about ₹75,589 at today's USD/INR rate, as of 25 Sep 2026, 4:00 PM ET, down 1.00% today. Indian residents can buy Regeneron Pharmaceuticals from India on Paasa under the RBI's Liberalised Remittance Scheme.

Quote

Open:$803.87
Previous close:$796.02
Volume:540.27K

Today's low

$784.13

Today's high

$803.87

52 week low

$541.00

52 week high

$859.34

REGN opened at $803.87, closed previously at $796.02, and has traded between $541.00 and $859.34 over the past 52 weeks.

About

Regeneron Pharmaceuticals, Inc. is a global biopharmaceutical enterprise focused on discovering, inventing, developing, manufacturing, and bringing to market medical treatments for a wide array of illnesses. Its therapeutic portfolio includes EYLEA, an injection used to treat various ophthalmic conditions such as wet age-related macular degeneration, diabetic macular edema, myopic choroidal neovascularization, diabetic retinopathy, and macular edema resulting from retinal vein occlusion (both central and branch). Other significant offerings are Dupixent, an injectable solution for atopic dermatitis and asthma in both adults and pediatric patients; Libtayo, indicated for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent, an injection prescribed for adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; REGEN-COV for COVID-19; and Kevzara, a solution targeting rheumatoid arthritis in adult patients. Furthermore, Regeneron provides Inmazeb for infections caused by Zaire ebolavirus; ARCALYST, an injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and Muckle-Wells syndrome; and ZALTRAP, an intravenous infusion used in the treatment of metastatic colorectal cancer. In addition to its existing product lineup, the company is actively engaged in developing novel product candidates aimed at addressing unmet medical needs in areas such as ocular diseases, allergic and inflammatory conditions, cardiovascular and metabolic disorders, infectious diseases, rare diseases, cancer, pain management, and hematologic conditions. Regeneron maintains extensive collaboration and licensing agreements with a diverse range of partners, including Sanofi, Bayer, Teva Pharmaceutical Industries Ltd., Mitsubishi Tanabe Pharma Corporation, Alnylam Pharmaceuticals, Inc., Roche Pharmaceuticals, and Kiniksa Pharmaceuticals, Ltd. It also holds agreements with entities such as the U.S. Department of Health and Human Services, Zai Lab Limited, Intellia Therapeutics, Inc., the Biomedical Advanced Research Development Authority, and AstraZeneca PLC. The company was founded in 1988 and its corporate headquarters are situated in Tarrytown, New York.

Country
US
CEO
Leonard S. Schleifer
Exchange listed on
NASDAQ
Industry
Biotechnology
Base currency
USD
Full Time Employees
15,410
Sector
Healthcare
IPO date
02/04/1991

Key statistics

Avg. volume

909.96K

Market cap

$81.19B

P/E Ratio

18.82

Price-to-sales ratio

5.23

Enterprise value

$80.72B

Free cash flow yield

4.34%

Debt-to-equity ratio

0.06

Return on equity

13.81%

ROIC

9.19%

Beta

0.24

Dividend yield

0.47%

Last dividend

$3.70

Financial overview

Revenue

$14.34B

Earnings per share

$43.07

Free cash flow

$4.08B

Net profit margin

27.86%

Gross margin

84.86%

EBITDA

$5.82B

Revenue growth

0.99%

Similar securities

This is not an investment recommendation

How to buy Regeneron Pharmaceuticals from India

Indian residents can buy Regeneron Pharmaceuticals shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.

  1. Open a Paasa account

    Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.

  2. Add funds under LRS

    Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.

  3. Search for Regeneron Pharmaceuticals and place an order

    Find Regeneron Pharmaceuticals by name or by its ticker, REGN, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Regeneron Pharmaceuticals trades 7:00 pm – 1:30 am IST; orders can only execute during that window.

  4. Track holdings and download tax reports

    Follow your Regeneron Pharmaceuticals position in USD and INR, and use Paasa's capital-gains and dividend statements when you file your Indian return.

Read the full guide: how to invest in Regeneron Pharmaceuticals from India

Trading and taxes when buying Regeneron Pharmaceuticals from India

Trading and limits

Trading hours
9:30 am – 4:00 pm ET
LRS limit
$250,000Per financial year, under the RBI's Liberalised Remittance Scheme.

Tax for Indian residents

TCS on remittance
20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
Capital gains in India
12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
Dividends
Slab rateDividends are taxed at your slab rate in India. The US withholds tax on dividends paid to Indian residents at the treaty rate; Paasa files Form W-8BEN for you, and the tax withheld can generally be claimed as a credit in India. Regeneron Pharmaceuticals’ current yield is 0.47%.Dividend tax explained
US estate tax
May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator

Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

FAQs

Can Indian residents buy Regeneron Pharmaceuticals stock?

Yes. Regeneron Pharmaceuticals (REGN) has been listed on NASDAQ since 1991, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.

How much does one Regeneron Pharmaceuticals share cost in rupees?

One Regeneron Pharmaceuticals share is $788.04 — about ₹75,589 at a USD/INR rate of 95.92 on 25 Sep 2026. Both the Regeneron Pharmaceuticals price and the rupee rate move during the day, so the rupee cost changes with them.

What are the LRS and TCS rules for buying Regeneron Pharmaceuticals from India?

Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.

Can I buy Regeneron Pharmaceuticals with less than the price of one share?

Yes. A whole Regeneron Pharmaceuticals share is $788.04, but there is no minimum trade size: you enter a rupee or dollar amount and receive the matching fraction.

How are gains on Regeneron Pharmaceuticals shares taxed in India?

The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Regeneron Pharmaceuticals price. Paasa issues a capital-gains statement for your return.

Does Regeneron Pharmaceuticals pay a dividend, and how is it taxed in India?

Yes. Regeneron Pharmaceuticals pays a dividend and the current yield is 0.47%; the last declared dividend was $3.70 per share, about ₹354.90. Dividends are taxed at your slab rate in India. The US withholds tax on dividends paid to Indian residents at the treaty rate; Paasa files Form W-8BEN for you, and the tax withheld can generally be claimed as a credit in India. Paasa's dividend report lists the gross dividend and any tax withheld for each payment.

When can I trade Regeneron Pharmaceuticals from India?

NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.

Is there estate or inheritance tax on Regeneron Pharmaceuticals shares held from India?

US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.

Do I have to declare Regeneron Pharmaceuticals shares in my Indian tax return?

Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Regeneron Pharmaceuticals holding, its cost and its closing value.

How do I sell Regeneron Pharmaceuticals and bring the money back to India?

You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.